Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Joanna Hernandez

Nurse Practitioner, Gerontology Warren, MI Nurse Practitioner

NPI 1548622251 CMS profile 11208205

28573 Schoenherr Rd, Warren, MI 48088

Open in the dashboard

General payments

$8,200

341 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Joanna Hernandez of Warren, MI is reported in the CMS Open Payments database as having received $8,200 across 341 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Nurse Practitioner, Gerontology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,100 132
2024 General $2,412 127
2023 General $1,770 69
2022 General $353 8
2021 General $565 5

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Joanna Hernandez
  • Nurse Practitioner, Gerontology median
  • Middle half of Nurse Practitioner, Gerontology
  • National median

In program year 2025, general payments to Joanna Hernandez were reported at $3,100. Among 4,139 Nurse Practitioner, Gerontology profiles paid that year, the median was $179 and the middle half received between $55 and $547.

Show as a table
Year Joanna Hernandez Nurse Practitioner, Gerontology median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $565 $133 $44–$396 $132
2022 $353 $142 $48–$452 $149
2023 $1,770 $158 $53–$482 $160
2024 $2,412 $171 $55–$533 $164
2025 $3,100 $179 $55–$547 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. UCB, Inc. $923 55 payments
  2. Novartis Pharmaceuticals Corporation $721 59 payments
  3. Neurelis, Inc. $693 23 payments
  4. Biogen, Inc. $691 27 payments
  5. Neurocrine Biosciences, Inc. $587 15 payments
  6. Teva Pharmaceuticals USA, Inc. $517 15 payments
  7. Alexion Pharmaceuticals, Inc. $470 7 payments
  8. EMD Serono, Inc. $457 22 payments
  9. LivaNova USA, Inc. $379 1 payment
  10. Pfizer Inc. $283 18 payments
  11. Other $2,480 99 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $7,744 339 payments
  2. Travel and Lodging $379 1 payment
  3. Education $76 1 payment
Products named General payments · program years 2021–2025
  1. KESIMPTA $721 59 payments
  2. VALTOCO $693 23 payments
  3. INGREZZA $587 15 payments
  4. VNS Therapy $379 1 payment
  5. Briviact $372 25 payments
  6. TYSABRI $358 13 payments
  7. ZEPOSIA $338 12 payments
  8. Nayzilam $313 16 payments
  9. VUMERITY $299 12 payments
  10. NURTEC ODT $283 18 payments
  11. Other $3,570 154 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 32 drugs

Part D claims

930

Median for Nurse Practitioner: 389

Drug cost

$415,457

Median for Nurse Practitioner: $21,885

Branded share of claims

18.9%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Austedo Deutetrabenazine Brand 17 $141,505
Vumerity Diroximel Fumarate Brand 12 $92,857
Briviact Brivaracetam Brand 41 $63,640
Epidiolex Cannabidiol (Cbd) Brand 12 $58,877
Valtoco Diazepam Brand 12 $19,798
Xcopri Cenobamate Brand 12 $13,936
Lacosamide Generic 38 $4,205
Levetiracetam Generic 82 $3,506
Memantine Hcl Generic 90 $3,043
Clobazam Generic 13 $1,886

The 10 drugs with the highest cost, of 32 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 13 billing codes

Paid by Medicare

$12,365

Medicare's payments for the services billed

Medicare patients

88

Average age 69

Services billed

167

52 women, 36 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 53%
Diabetes 42%
Depression 42%
Ischemic heart disease 41%
Chronic kidney disease 39%
Alzheimer's or dementia 36%
Heart failure 25%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 28 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
KESIMPTA
  • Novartis Pharmaceuticals Corporation $332
$332 — —
INGREZZA
  • Neurocrine Biosciences, Inc. $296
$296 — —
VALTOCO
  • Neurelis, Inc. $212
$212 12 —
Briviact
  • UCB, Inc. $164
$164 41 —
VUMERITY
  • Biogen, Inc. $143
$143 12 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 28 with Patron

Records

341 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Gerontology in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record